We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Discharge Via an Intermediate Care Unit

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01706744
First Posted: October 15, 2012
Last Update Posted: December 8, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Norwegian University of Science and Technology
  Purpose

The main goal is to investigate the following topics:

  1. Can discharge via the Intermediate Care Unit in Stjørdal, compared to direct discharge to Verdal Municipality, be equally effective in preventing aggravation of disease and loss of function for patients over 60 years that have been hospitalized in Levanger hospital?
  2. Are the cost by discharge to the Intermediate Care Unit in Stjørdal, when the hospital is not located in the same Municipality, comparable to the cost by direct discharge to the Municipality of Verdal, for patients over 60 years that have been hospitalized in Levanger hospital?
  3. Which issues are considered important by patients and health personnel during discharge, arrival and follow up in the Municipality, to ensure an optimal interaction between the involved units.

Condition Intervention
Patients Aged Other: Intermediate care unit Other: Local health care 1 Other: Local health care 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Can Discharge Via an Intermediate Care Unit Prevent Aggravation of Disease and Loss of Functionality, Without Increasing the Level of Cost? A Controlled Observational Study

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • Hospital readmission [ Time Frame: 30 days ]
    Acute admission to hospital within 30 days from previous discharge

  • Use of local health care services [ Time Frame: up to 1 year ]

Secondary Outcome Measures:
  • death [ Time Frame: up to 1 year ]
  • hospital admission [ Time Frame: up to 1 year ]
  • functional assessment status [ Time Frame: up to 6 months ]
  • Health service cost [ Time Frame: up to 1 year ]

Enrollment: 328
Study Start Date: February 2010
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intermediate care unit
Follow-up treatment and care in a intermediate care unit after discharge from hospital
Other: Intermediate care unit
Active Comparator: Local health care 1
Discharge from hospital to usual care as provided by the local health and social care (Verdal)
Other: Local health care 1
Active Comparator: Local health care 2
Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
Other: Local health care 2

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients 60 years old or older from Stjørdal- or Verdal municipality,

  • given consent,
  • admitted from their home,
  • diagnostics completed and necessary treatment started
  • the patient need not less than 3-4 days institutionalization for treatment/rehabilitation/care

Exclusion Criteria:

  • Patients with severe dementia
  • Patients with severe disease who cannot give consent
  • Patients with severe disease with short life expectancy (including severe cancer)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01706744


Locations
Norway
Sykehuset Levanger
Levanger, Norway
Distriksmedisinsk Senter
Stjørdal, Norway
Stjørdal Kommune
Stjørdal, Norway
Verdal kommune
Verdal, Norway
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Study Director: Roar Johnsen, PhD Norwegian University of Science and Technology